Home >> Signaling Pathways >> Apoptosis

Apoptosis(凋亡)

As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.

Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.

Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.

Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.

Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.

Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.

One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.

p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.

Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9). 

Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.

References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.

Products for  Apoptosis

  1. Cat.No. 产品名称 Information
  2. GC33052 VU0661013 VU661013 is a novel, potent, selective MCL1 inhibitor with Ki of 97 ± 30 pM of human MCL-1 in a TR-FRET assay. However, VU661013 does not significantly inhibit BCL-xL or BCL-2 with Ki > 40 μM or = 0.73 μM. VU661013 de-stabilizes BIM/MCL-1 association, leads to apoptosis in AML.
  3. GC33043 EL-102 EL102是HIF1α的抑制剂,能够抑制微管蛋白聚合和减少它的稳定性。
  4. GC33035 Mcl1-IN-2

    7-[(2-吡啶基氨基)-2-噻吩基甲基]-8-喹啉醇

    Mcl1-IN-2 是骨髓细胞因子 1 (Mcl-1) 的抑制剂。 Mcl1-IN-2 是一种非竞争性的德里 metallo-β-lactamase (NDM-1) 抑制剂。 MCL1-IN-2对Metallo-&7#8946; -lactamases NDM-1,IMP-4,IMIS和L1的IC50S是0.4637 &##956; M,M,3.980 &&####&&7778777878787878787878787878787878787878787787877年7月778.7887;offlineefficient_models_2022q2.md
  5. GC33029 Forodesine (BCX-1777 freebase)

    呋咯地辛; BCX-1777; Immucillin-H

    A nucleoside analog and PNP inhibitor
  6. GC33002 PBOX 6 PBOX6是一种pyrrolo-1,5-benzoxazepine(PBOX)化合物,可作为微管解聚剂和促凋亡剂起作用。
  7. GC32998 Ginsenoside Rh4

    人参皂苷RH4

    Ginsenoside Rh4 is an important active ingredient of traditional Chinese medicine ginseng, which has been shown to inhibit Wnt/β-Catenin, JAK2/STAT3, TGF-β/Smad2/3 and other signaling pathways.
  8. GC32997 Cinchonine ((8R,9S)-Cinchonine)

    辛可宁; (8R,9S)-Cinchonine; LA40221

    Cinchonine (LA40221) is an alkaloid and a stereoisomer and pseudo-enantiomer of cinchonidine.
  9. GC32981 A-385358 A-385358是Bcl-XL的一个选择性抑制剂,对于Bcl-XL和Bcl-2的Ki值分别为0.80和67nM。
  10. GC32973 SID 3712249 (MiR-544 Inhibitor 1)

    MiR-544 Inhibitor 1

    An inhibitor of miR-544 biogenesis
  11. GC32947 S55746 (BLC201)

    BCL201

    S55746 (S 055746,BCL201) is a novel, orally active BCL-2 specific inhibitor (Ki = 1.3 nM) with poor affinity for BCL-XL and no significant binding to MCL-1, BFL-1 (BCL2A1/A1). The selectivity of S55746 for BCL-2 versus BCL-XL ranges from ~70 to 400 folds.
  12. GC32946 PK11007 PK11000 stabilizes the DBD of both WT and mutant p53 proteins by covalent cysteine modification without compromising DNA binding and effective in inducing cell death.
  13. GC32929 MIR96-IN-1 MIR96-IN-1选择性抑制微小RNA-96的生物合成,上调蛋白靶点(FOXO1)且诱导癌细胞凋亡。
  14. GC32919 Kevetrin hydrochloride (4-Isothioureidobutyronitrile hydrochloride)

    4-Isothioureidobutyronitrile hydrochloride; thioureidobutyronitrile hydrochloride; thioureido butyronitrile hydrochloride

    An activator of p53
  15. GC32911 CTX1

    CTX1是一种新型小分子p53激活剂。

  16. GC32901 ROC-325 An autophagy inhibitor
  17. GC32895 Maytansinol (Ansamitocin P-0)

    美登醇,Ansamitocin P-0

    An ansa macrolide
  18. GC32881 Milademetan (DS-3032)

    DS-3032

    Milademetan (DS-3032) (DS-3032) 是一种特异性的、具有口服活性的 MDM2 抑制剂,用于研究急性髓性白血病 (AML) 或实体瘤。 Milademetan (DS-3032) (DS-3032) 诱导 G1 细胞周期停滞、衰老和凋亡。
  19. GC32860 RIP2 kinase inhibitor 2 RIP2kinaseinhibitor2是一种受体相互作用蛋白-2(RIP2)激酶抑制剂,详细信息请参考专利WO/2014043437A1中的化合物example9。
  20. GC32853 PD0166285

    6-(2,6-二氯苯基)-2-[[4-[2-(二乙基氨基)乙氧基]苯基]氨基]-8-甲基吡啶并[2,3-D]嘧啶-7(8H)-酮

    PD0166285 is a potent Wee1 and Chk1 inhibitor with activity at nanomolar concentrations (IC50=24 nM for Wee1 and 72 nM for Myt1). PD0166285 is also a novel G2 checkpoint abrogator. PD0166285 induces apoptosis.
  21. GC32841 Catechin ((+)-Catechin)

    儿茶素; (+)-Catechin; Cianidanol; Catechuic acid

    (+)-Catechin (Cianidanol, Catechinic acid, Catechuic acid) is an antioxidant flavonoid, occurring especially in woody plants as both (+)-catechin and (-)-epicatechin (cis) forms.
  22. GC32807 HJC0152 hydrochloride

    2-(2-氨基乙氧基)-5-氯-N-(2-氯-4-硝基苯基)苯甲酰胺盐酸盐

    An orally bioavailable inhibitor of STAT3
  23. GC32803 ASTX660

    Tolinapant

    A non-peptidomimetic inhibitor of IAP protein-peptide interactions
  24. GC32781 CUDC-427 (GDC-0917)

    GDC-0917

    CUDC-427 (GDC-0917) 是一种有效的第二代泛选择性 IAP 拮抗剂,用于治疗各种癌症。
  25. GC32775 RIP2 kinase inhibitor 1 GSK2983559 active metabolite is an active metabolite of GSK2983559, also is a receptor interacting protein-2 (RIP2) kinase inhibitor extracted from patent WO/2014043446 A1, compound example 1.
  26. GC32767 3BDO

    3BDO,MTOR激酶激活剂,自噬抑制剂

    A butyrolactone derivative and autophagy inhibitor
  27. GC32762 Icaritin (Anhydroicaritin)

    去水淫羊藿黄素

    An FASN inhibitor
  28. GC32753 Taltobulin (HTI-286)

    N,BETA,BETA-三甲基-L-苯基丙氨酰基-N-[(1S,2E)-3-羧基-1-(1-甲基乙基)-2-丁烯基]-N,3-二甲基-L-缬氨酰胺,HTI-286; SPA-110

    An inhibitor of microtubule polymerization
  29. GC32737 TAK-243 (MLN7243)

    MLN7243

    A UAE inhibitor
  30. GC32731 OSU-T315 (ILK-IN-1)

    OSU-T315 analog

    An ILK inhibitor
  31. GC32729 Rhosin hydrochloride

    G04

    An inhibitor of the Rho-GEF protein-protein interaction
  32. GC32724 LW6 (HIF-1α inhibitor)

    HIF-1α inhibitor; LW8

    LW6是一种缺氧诱导因子1(hypoxia inducing factor 1, HIF)抑制剂,通过降解HIF-1α有效抑制HIF-1α的积累,但不影响缺氧时HIF- 1a mRNA水平。
  33. GC32723 CDDO-Im (RTA-403)

    RTA-403; TP-235; CDDO-Imidazolide

    An activator of Nrf2 signaling
  34. GC32719 dBET6 A PROTAC that drives BRD4 degradation
  35. GC32710 GDC-0077 (RG6114)

    GDC-0077; RG6114

    Inavolisib (GDC-0077, RG6114, RO-7113755) is a potent selective inhibitor of PI3K alpha (PI3Kα) with an IC50 of 0.038 nM. GDC-0077 is >300-fold more selective for PI3K alpha over the other class I PI3K isoforms (beta, delta, and gamma) and >2000-fold more selective over PIK family members. GDC-0077 binds to the ATP binding site of PI3K and inhibits the phosphorylation of PIP2 to PIP3.
  36. GC32708 Forodesine hydrochloride (BCX-1777)

    BCX-1777 hydrochloride; Immucillin-H hydrochloride

    A nucleoside analog and PNP inhibitor
  37. GC32704 Atezolizumab (MPDL3280A)

    阿特珠单抗; MPDL3280A

    Atezolizumab 是一种针对 PD-L1 的特异性单克隆抗体,可以抑制 PD-L1 和 PD-1 之间的结合。
  38. GC32695 Ac-DEVD-CHO Ac-DEVD-CHO是一种Caspase-3抑制剂,IC50值为0.016μM。
  39. GC32692 APTO-253 (LOR-253)

    LOR-253; LT-253

    APTO-253 是一种新型小分子,通过诱导 Kruppel 样因子 4 (KLF4) 主转录因子基因表达,从而抑制细胞周期并导致程序性细胞死亡,发挥强大的抗肿瘤活性。
  40. GC32687 Takinib

    EDHS-206

    A TAK1 inhibitor
  41. GC32681 GSK2795039 A NOX2 inhibitor
  42. GC32587 Clofilium tosylate

    氯非铵甲苯磺酸盐

    Clofiliumtosylate是一种钾通道(potassiumchannel)阻滞剂,作用于人早幼粒细胞白血病(HL-60)细胞,激活caspase-3而诱导凋亡。具有抗心律失常作用。
  43. GC32391 Pyrogallol

    邻苯三酚

    A natural oxidant
  44. GC32280 HS-1371 A RIPK3 inhibitor
  45. GC32186 Puromycin (CL13900)

    嘌呤霉素二盐酸盐水合物

    Puromycin 2HCl (CL13900) is an aminonucleoside antibiotic, which acts as a protein synthesis inhibitor.

  46. GC32138 Furazolidone

    呋喃唑酮

    A nitrofuran antiprotozoal and antibacterial agent
  47. GC32127 Alofanib (RPT835)

    RPT835

    An allosteric inhibitor of FGFR2
  48. GC32066 RRx-001

    ABDNAZ

    RRx-001 是一种源自航空航天的抗癌剂,具有产生活性氮物质 (RNS) 的化学作用,可导致表观遗传改变,例如癌细胞中的 DNA 甲基化和组蛋白乙酰化。
  49. GC31905 TNF-α-IN-1 TNF-α-IN-1是TNF-α抑制剂,来自专利US20030096841A1,化合物实例I-7.
  50. GC31892 Decursin ((+)-Decursin)

    紫花前胡素; (+)-Decursin

    A phytochemical with diverse biological activities
  51. GC31886 Chelidonic acid

    白屈菜酸

    A pyran with diverse biological activities

Items 1551 to 1600 of 2517 total

per page

Set Descending Direction